EBITDA: Income before interest, taxes, depreciation and amortization.
Ovid Therapeutics (OVID) had EBITDA of $-12.28M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.72M |
|
$9.66M |
|
-- |
|
$0.72M |
|
$13.01M |
|
$-12.29M |
|
$21.96M |
|
$9.66M |
|
$9.66M |
|
$9.66M |
|
$9.66M |
|
$9.66M |
|
$9.66M |
|
$-12.29M |
|
|
EBITDA |
$-12.28M |
73.74M |
|
73.74M |
|
$0.14 |
|
$0.14 |
|
| Balance Sheet Financials | |
$74.37M |
|
$0.25M |
|
$76.57M |
|
$150.93M |
|
$8.29M |
|
$11.99M |
|
$11.99M |
|
$20.27M |
|
$130.66M |
|
$130.66M |
|
$130.66M |
|
130.18M |
|
| Cash Flow Statement Financials | |
$-38.33M |
|
$-49.85M |
|
$75.21M |
|
$28.23M |
|
$15.08M |
|
$-13.15M |
|
$4.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.97 |
|
-- |
|
-- |
|
0.08 |
|
0.10 |
|
100.00% |
|
-1712.12% |
|
-1712.12% |
|
-- |
|
1345.82% |
|
1345.82% |
|
$-38.33M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
7.40% |
|
7.40% |
|
6.40% |
|
6.77% |
|
$1.00 |
|
$-0.52 |
|
$-0.52 |
|